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Copy number variation
Traditional  cytogenetic  approaches  first  showed  that 
variations  in  chromosome  copy  number  could  cause 
disease in humans. However, it is only with the recent 
advances in genome scanning technology that screening 
for human structural mutations and their role in disease 
susceptibility  has  really  come  into  the  limelight. 
Completion of the human genome project showed that 
copy  number  variation  is  a  widespread  and  common 
phenomenon  in  humans  [1].  A  copy  number  variant 
(CNV) is a region of DNA in which allelic-number differ-
ences have been found by comparison of two or more 
independent genomes. These DNA segments may range 
from  less  than  one  kilobase  (kb)  to  several  megabases 
(Mb) in size and can be caused by genomic rearrange-
ments such as deletions, multiplications, inversions and 
translocations  [2].  The  vast  majority  of  CNVs  are 
unbalanced, may be limited to a single gene or include a 
contiguous set of genes and can either be inherited or 
caused  by  de  novo  events.  Altered  expression  levels  of 
these  CNV  genes  may  be  responsible  for  observed 
phenotypic  variability,  complex  behavioral  traits  and 
disease susceptibility. So far, CNVs have been implicated 
in  the  pathogeneses  of  several  neurological  disorders, 
including Parkinson’s disease (PD) [3,4].
Parkinson’s disease
PD  is  a  common  neurodegenerative  disorder  affecting 
approximately 1% of the population aged over 60 years. 
The disease presents clinically as a movement disorder 
characterized by tremor at rest, bradykinesia, rigidity and 
postural instability. Neuropathological changes leading to 
a  diagnosis  of  PD  are  dopaminergic  cell  loss  in  the 
substantia nigra accompanied by the formation of Lewy 
bodies,  which  are  intracytoplasmic  protein  aggregates 
within the remaining neurons. The neuropathology asso-
ciated  with  PD  progresses  over  time,  and  in  more 
advanced stages, patients develop a range of non-motor 
symptoms, including cognitive decline. Although drugs 
such  a  levodopa  or  surgical  intervention  (deep  brain 
stimulation) can help alleviate the motor symptoms, they 
do  not  halt  disease  progression  and  are  not  effective 
against  the  non-motor  aspects  of  the  disease,  such  as 
rapid eye movement sleep behavior disorder, constipa-
tion, depression and cognitive decline.
A major breakthrough in recent years has been the 
mapping  of  chromosomal  loci  linked  to  familial  PD 
and the cloning of five genes causing monogenic forms 
of  the  syndrome  [5].  Mendelian  forms  of  PD  are 
relatively rare and the genetic mutations account for 
only a small fraction of affected individuals; however, 
common  varia  tion  at  some  of  these  loci  has  been 
shown to confer population disease risk in association-
based studies. The identification of CNVs in several of 
these genes has provided mechanistic insights into PD 
pathogenesis,  generated  in  vivo  model  systems  and 
driven  the  development  of  novel  therapeutic  inter-
vention strategies.
Abstract
A central theme of human genetic studies is to 
understand genomic variation and how this underlies 
the inherited basis of disease. Genomic variation 
can provide increased biological understanding of 
disease processes, which is necessary to develop 
future treatments. Recent technological advances 
have highlighted the role of copy number variants 
in normal and pathological phenotypic expression. 
These applications have been used in studies of 
Parkinson’s disease, a common, late-onset, progressive 
neurodegenerative disorder. At present the main 
therapeutic approach is administration of symptom-
alleviating drugs, which neither reverses the disease 
process nor halts its progression. However, the 
generation of in vivo model systems and development 
of novel disease intervention strategies for Parkinson’s 
disease have come from research on monogenic 
forms of the disorder, including those caused by copy 
number variants. Here, we review the role of copy 
number variants and the mechanistic insights they have 
provided on the pathogenesis of Parkinson’s disease.
© 2010 BioMed Central Ltd
Copy number variation in Parkinson’s disease
Mathias Toft1 and Owen A Ross*2
MINIREVIEW
*Correspondence: ross.owen@mayo.edu 
2Department of Neuroscience, Mayo Clinic Jacksonville, 4500 San Pablo Road 
South, Jacksonville, FL 32224, USA 
Full list of author information is available at the end of the article
Toft and Ross Genome Medicine 2010, 2:62 
http://genomemedicine.com/content/2/9/62
© 2010 BioMed Central LtdPathogenic copy number variation in autosomal 
dominant Parkinson’s disease
A seminal discovery in the study of PD was the report of 
missense mutations in the SNCA gene, encoding the α-
synuclein  protein,  in  dominantly  inherited  disease  [6]. 
This was the first evidence that genomic variation could 
result in an inherited form of PD. The subsequent identi-
fication of α-synuclein as the major protein component 
of  the  pathological  substrate  (Lewy  bodies)  placed  α-
synuclein  at  the  center  of  PD  research.  However,  the 
missense mutations reported in SNCA provided limited 
insight into the pathological mechanisms involved.
In  2003,  genomic  multiplications  of  chromosome 
4q21-22 containing the SNCA locus were shown to cause 
familial PD (Figure 1). Genomic triplication of the gene 
causes a rapidly progressive form of PD [4]. In contrast, 
the clinical phenotype of families with a duplication of 
SNCA resembles idiopathic PD with late age at onset and 
slower  disease  progression  and  without  early  develop-
ment  of  dementia.  Several  asymptomatic  duplication 
carriers over 70 years of age without any signs of PD have 
recently been identified, indicating a reduced penetrance 
of  disease  [7].  Segmental  intra-allelic  duplication  and 
interallelic  recombination  with  unequal  crossing-over 
Figure 1. A representation of (a) Affymetrix 250k SNP microarrays and (b) fluorescent in situ hybridization (FISH) that were used to 
identify a region of duplication containing the SNCA gene (highlighted by the box). (a) Relative copy number estimates for SNCA duplication 
are plotted against physical genomic position on chromosome 4. Raw data are shown that have not been normalized with respect to integers. 
(b) FISH was performed on interphase cells with three labeled SNCA probes directed at the entire locus (PAC 27M07, green), at the promoter and at 
intron 4 fragments (red).
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[8].  Measurements  of  protein  levels  in  triplication 
carriers confirmed the predicted doubling of α-synuclein 
protein in blood and increased levels of the protein in the 
brain.  Therefore,  even  without  sequence  mutants, 
increased wild-type α-synuclein dosage may cause PD.
Recent  studies  have  confirmed  the  association  of 
common non-coding genetic variants at the SNCA locus 
and increased risk of PD [9]. These findings suggest that 
variation  in  regions  of  SNCA,  most  likely  deregulating 
constitutive  gene  overexpression,  may  provide  a  thera-
peutic target to a substantial proportion of patients with 
the  more  frequent  sporadic  form  of  PD.  Currently, 
studies are underway to generate in vivo SNCA multi  pli-
cation model systems and identify sensitive and specific 
downregulators of SNCA gene and protein expression.
Recessive forms of PD
Whereas  the  SNCA  story  suggests  a  gain  of  function, 
several  early-onset  forms  of  PD-like  disorders  have 
demon  strated the role of loss of function in the disease. 
The  Parkin  (PRKN)  gene  is  one  of  the  largest  known 
genes, spanning a 1.4 Mb genomic region. PRKN muta-
tions  are  the  most  common  cause  of  early-onset  PD 
identified  so  far  and  are  particularly  frequent  in 
individuals  with  evidence  of  recessive  inheritance.  The 
initial pathogenic PRKN mutations identified were large 
homozygous  genomic  deletions,  and  more  than  100 
different pathogenic variants in this gene have been pub-
lished, including deletions, multiplications and missense 
and nonsense mutations [10]. The PRKN gene is located 
in one of several genomic regions of very high deletion 
frequency (‘hotspots’), where independent rare deletions 
are found at frequencies of up to 100-fold higher than the 
average for the genome as a whole [11]. Approximately a 
third of all pathogenic PRKN variants are CNVs occur-
ring between exons 2 and 5, forming a recombination hot 
spot [10].
Pathogenic  mutations  in  the  PTEN-induced  kinase 
(PINK1) gene are much less common than PRKN muta-
tions and probably account for only 1 to 2% of early-onset 
PD  patients.  CNVs  in  families  with  PD  have  been 
reported, including a deletion of the entire PINK1 gene 
[12]. This deletion also partly involved two neighboring 
genes,  and  two  highly  similar  AluJo  repeat  sequences 
within these genes were found, which enclose the puta-
tive  breakpoints.  It  is  likely  that  the  deletion  resulted 
from  an  unequal  crossing-over  between  these  two 
sequen  ces.  Furthermore,  a  homozygous  deletion  of 
PINK1 exons 4 to 8 was found in three affected siblings 
from a consanguineous Sudanese family with early-onset 
PD [13]. Breakpoint analysis revealed a complex rearrange-
ment combining a large deletion and the insertion of a 
sequence  duplicated  from  the  neighboring  dolichyl-
diphospho  oligosaccharide-protein  glycosyltransferase 
(DDOST) gene.
The PARK7 locus on chromosome 1p36 was localized 
by  homozygosity  mapping  in  two  consanguineous 
families  from  genetically  isolated  communities  in  the 
Netherlands  and  Italy.  In  one  of  the  families,  a  14  kb 
deletion involving the first five of seven exons in the DJ-1 
gene was identified [14]. The DJ-1 protein is involved in 
oxidative  stress  response  and  may  be  targeted  to  the 
mitochondria.  Alu  repeat  elements  flank  the  deleted 
sequence on both sides, suggesting that unequal crossing-
over was likely at the origin of this genomic rearrange-
ment.  Very  few  mutations  in  this  gene  have  been 
reported, and mutation of DJ-1 accounts for less than 1% 
of  early-onset  PD  cases.  A  heterozygous  duplication 
involving the first five exons of DJ-1 in a single patient is 
the only other CNV published so far [15].
Genome-wide association studies
Genome-wide association studies (GWASs) have helped 
to elucidate the genetic basis for a number of complex 
disorders.  GWASs  use  microarrays  with  up  to  one 
million  single  nucleotide  polymorphisms  (SNPs)  to 
capture  a  significant  amount  of  an  individual’s  genetic 
variation. In addition to identification of SNPs associated 
with  disease,  these  studies  also  allow  quantitative 
assessment of the genome. A total of five GWASs of PD 
have been published so far. However, analyses of struc-
tural genetic variation have been published from only a 
relatively small study of 273 patients [16]. No new regions 
associated with PD were identified, but several deletions 
and duplications in the PRKN gene were observed. The 
potential  power  of  this  approach  in  PD  and  other 
neurodegenerative disorders has yet to be fully used.
Conclusions
A  recent  study  of  eight  common  diseases  (including 
coronary  artery  disease,  rheumatoid  arthritis  and 
diabetes) concluded that common CNVs are unlikely to 
have a major pathogenic role [17]. However, this does not 
exclude  the  possible  existence  of  several  rare  CNVs 
causing the same disorders in a proportion of patients. 
The  number  of  individuals  carrying  a  given  CNV  at  a 
known  gene  locus  is  frequently  small.  Nevertheless, 
discovery of these changes by GWASs or family-based 
studies are important.
Limited data from GWASs have been published on the 
extent  of  CNVs  in  PD,  even  though  previous  family-
based studies have highlighted CNVs in both familial and 
sporadic PD. A large proportion of functional and trans-
lational  PD  research  today  is  based  on  hypotheses 
provided  by  the  identification  of  mutations  in  familial 
forms of the disorder, including CNVs. The most common 
genetic cause of PD is point mutations in the leucine-rich 
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identified at this locus. The hypothesized toxic gain of 
function (kinase activity) would be supported if LRRK2 
multiplications are identified. The SNCA story in PD has 
shown how the identification of a single CNV can provide 
insights  into  pathogenic  mechanisms  and  drive  thera-
peutic  development,  and  although  it  remains  unclear 
what proportion of genetic disease is caused by CNVs, it 
is likely that many of those affecting risk of PD are still to 
be identified.
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